Video

Dr. Ko on Unmet Needs in PD-L1–Negative TNBC

Author(s):

Heidi Ko, DO, discusses unmet needs in patients with PD-L1–negative triple negative breast cancer.

Heidi Ko, DO, assistant professor of Medicine, medical oncologist, Mays Cancer Center at UT Health San Antonio, discusses unmet needs in patients with PD-L1–negative triple negative breast cancer (TNBC).

Chemotherapy remains the standard-of-care frontline therapy for patients with PD-L1–negative TNBC, and there have not been many data collected from clinical trials regarding this patient population, Ko says. Future studies examining the use of immunotherapy in combination with antibody-drug conjugates or other targeted agents as a first-line therapy could produce other potential treatment options for these patients, Ko explains.

Notably, ongoing studies are examining the frontline use of a PARP inhibitor plus immunotherapy in patients with TNBC harboring BRCA mutations, and these studies include patients with PD-L1–positive and –negative disease, Ko concludes.

Related Videos
Jonathan Spicer, MD, PhD, FRCS
Daniel DeAngelo, MD, PhD
Marc J. Braunstein, MD, PhD, associate professor, Department of Medicine, co-director, Hematology-Oncology System, New York University (NYU) Grossman Long Island School of Medicine
Douglas W. Sborov, MD, MS, associate professor, Department of Internal Medicine—Division of Hematology and Hematologic Malignancies; director, Hematology Disease Center and Plasma Cell Dyscrasias Program, the University of Utah Huntsman Cancer Institute
Bradley C. Carthon, MD, PhD
David C. Fisher, MD
Alan Tan, MD
Binod Dhakal, MD
Sheldon M. Feldman, MD
Yair Lotan, MD, UT Southwestern Medical Center